Phase III Study of AZD3470 Alone or With Pembrolizumab in Adults and Adolescents With Blood Cancers Including Hodgkin and Peripheral T-cell Lymphomas

What this Trial Is About

Researchers are investigating AZD3470, a new oral drug, alone or combined with other cancer-fighting agents, in people with various blood cancers. This Phase III, open-label study aims to assess the safety, tolerability, how the drug moves through and affects the body, and early signs of effectiveness. The study includes adults and adolescents with relapsed or refractory classical Hodgkin lymphoma cHL, peripheral T-cell lymphoma PTCL, and other types of blood cancers, focusing on both monotherapy and combination treatments. The study is divided into several modules and cohorts. Module 1 Cohort 1 tests AZD3470 alone in adults and adolescents with relapsed or refractory cHL who have had at least two previous therapies, including certain anticancer drugs. Module 1 Cohort 2 evaluates AZD3470 as a consolidation treatment for older adults with advanced cHL who responded to frontline therapy. Module 1 Cohort 3 focuses on relapsed or refractory PTCL patients receiving AZD3470 monotherapy. Module 2 Cohort 1 assesses AZD3470 combined with pembrolizumab in relapsed or refractory cHL patients. Each cohort has dose escalation and expansion phases to determine optimal dosing and safety. Participants will have regular safety and response assessments, including scans and tissue samples, throughout treatment cycles lasting 21 days each. Researchers will monitor adverse events, drug levels in the body, and tumor responses using established criteria. The study will continue until disease progression, unacceptable side effects, or other defined criteria. Follow-up includes safety monitoring 28 days after the last dose. The total duration depends on individual treatment response and tolerability.

AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.